Pharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreak - IFPMA

A rapidly escalating outbreak of Ebola Bundibugyo virus disease (BVD) in the Democratic Republic of Congo (DRC) and Uganda has triggered an urgent, multi-pronged response from the pharmaceutical industry, global health bodies, and research institutions. With over 550 confirmed cases and at least 90 deaths reported by early June 2026, the World Health Organization (WHO) declared the situation a Public Health Emergency of International Concern (PHEIC) on May 17, underscoring the severe cross-border risk and the critical lack of approved vaccines or treatments specifically for the Bundibugyo strain. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has confirmed that pharmaceutical and biotech companies are actively engaged in a coordinated effort, accelerating the development of medical countermeasures. The Coalition for Epidemic Preparedness Innovations (CEPI) has fast-tracked funding for three experimental vaccine candidates from IAVI, Moderna, and the University of Oxford, with trials expected to begin in months. These efforts leverage diverse platforms, including mRNA and ChAdOx1, aiming to either achieve cross-protection from existing Ebola vaccines or develop novel, strain-specific solutions, alongside prioritizing monoclonal antibodies and direct-acting antivirals for clinical testing. The immediate focus is on rapidly moving these promising candidates through clinical trials, drawing lessons from the expedited development during the COVID-19 pandemic while navigating significant logistical and security challenges posed by armed groups in affected regions of the DRC. While the case fatality rate for this outbreak stands at approximately 17.4%, lower than some past Ebola outbreaks, the continued spread and the absence of proven medical tools necessitate sustained, rapid global collaboration to contain the epidemic and bolster preparedness for future viral threats.